391 related articles for article (PubMed ID: 2174343)
21. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
23. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
Csernus VJ; Szende B; Groot K; Redding TW; Schally AV
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):111-8. PubMed ID: 2110458
[TBL] [Abstract][Full Text] [Related]
24. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
25. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
Halmos G; Arencibia JM; Schally AV; Davis R; Bostwick DG
J Urol; 2000 Feb; 163(2):623-9. PubMed ID: 10647698
[TBL] [Abstract][Full Text] [Related]
26. The presence of LHRH-like receptors in Dunning R3327H prostate tumors.
Hierowski MT; Altamirano P; Redding TW; Schally AV
FEBS Lett; 1983 Apr; 154(1):92-6. PubMed ID: 6299799
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
Ayalon D; Farhi Y; Comaru-Schally AM; Schally AV; Eckstein N; Vagman I; Limor R
Neuroendocrinology; 1993 Aug; 58(2):153-9. PubMed ID: 8264861
[TBL] [Abstract][Full Text] [Related]
28. Decreased ability of old male rats to secrete luteinizing hormone (LH) is not due to alterations in pituitary LH-releasing hormone receptors.
Sonntag WE; Forman LJ; Fiori JM; Hylka VW; Meites J
Endocrinology; 1984 May; 114(5):1657-64. PubMed ID: 6325129
[TBL] [Abstract][Full Text] [Related]
29. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
30. Effect of [D-Trp6]LHRH infusion on prolactin secretion by perifused rat pituitary cells.
Torres-Aleman I; Fernández M; Debeljuk L; Charro AL
Regul Pept; 1987 Jul; 18(1):19-28. PubMed ID: 2957725
[TBL] [Abstract][Full Text] [Related]
31. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity.
Marchetti B; Guarcello V; Morale MC; Bartoloni G; Raiti F; Palumbo G; Farinella Z; Cordaro S; Scapagnini U
Endocrinology; 1989 Aug; 125(2):1037-45. PubMed ID: 2546733
[TBL] [Abstract][Full Text] [Related]
32. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
Szepeshazi K; Korkut E; Szende B; Lapis K; Schally AV
Prostate; 1991; 18(3):255-70. PubMed ID: 2020621
[TBL] [Abstract][Full Text] [Related]
33. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.
Bajusz S; Csernus VJ; Janaky T; Bokser L; Fekete M; Schally AV
Int J Pept Protein Res; 1988 Dec; 32(6):425-35. PubMed ID: 2469662
[TBL] [Abstract][Full Text] [Related]
34. Androgens decrease LHRH binding sites in rat anterior pituitary cells in culture.
Giguere V; Lefebvre FA; Labrie F
Endocrinology; 1981 Jan; 108(1):350-2. PubMed ID: 6257490
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
37. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
Horvath JE; Bajo AM; Schally AV; Kovacs M; Herbert F; Groot K
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15048-53. PubMed ID: 12409615
[TBL] [Abstract][Full Text] [Related]
38. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
Pinski J; Yano T; Miller G; Schally AV
Prostate; 1992; 20(3):213-24. PubMed ID: 1533453
[TBL] [Abstract][Full Text] [Related]
39. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
[TBL] [Abstract][Full Text] [Related]
40. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
